The Medicines Company (MDCO) PT Raised to $60 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Medicines Co. (MDCO) Highlights Results from ORION-11, First Ph. 3 Trial of Inclisiran, Showing Durable & Potent Lowering of LDL-C with Twice-Yearly Dosing
September 3, 2019 5:54 AM EDTThe Medicines Company (NASDAQ: MDCO) today announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol (LDL-C) and the first and only cholesterol-lowering therapy in the siRNA (small-interfering RNA or sir-nah)... More
The Medicines Company (MDCO) PT Raised to $50 at Cowen
September 3, 2019 5:41 AM EDTCowen analyst Chris Shibutani raised the price target on The Medicines Company (NASDAQ: MDCO) to $50.00 (from $46.00) while maintaining a Outperform rating.
... MoreThe Medicines Company (MDCO) PT Raised to $74 at B.Riley/FBR
September 3, 2019 5:09 AM EDTB.Riley/FBR analyst Mayank Mamtani raised the price target on The Medicines Company (NASDAQ: MDCO) to $74.00 (from $61.00) while maintaining a Buy rating.
... More